2-chloro-7-pyridin-2-yl-7H-pyrrolo[2,3-d]pyrimidine | 863599-38-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯并嘧啶类
• 英文名称: 2-chloro-7-pyridin-2-yl-7H-pyrrolo[2,3-d]pyrimidine
• 英文别名: 2-chloro-7-pyridin-2-ylpyrrolo[2,3-d]pyrimidine
• CAS: 863599-38-6
• 化学式: C₁₁H₇ClN₄
• 分子量: 230.656
• InChiKey: IPEHJECXGDLQLV-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  16
• 可旋转键数：
  1
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  43.6
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  2-chloro-7-pyridin-2-yl-7H-pyrrolo[2,3-d]pyrimidine 在 potassium tert-butylate 作用下， 以 四氢呋喃 为溶剂， 反应 2.0h， 生成 (7-pyridin-2-yl-7H-pyrrolol[2,3-d]pyrimidin-2-yl)-(3,4,5,-trimethoxy-phenyl)-amine
  参考文献：
  名称：

  [EN] COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS
  [FR] COMPOSES ET COMPOSITIONS TENANT LIEU D'INHIBITEURS DE LA PROTEINE KINASE

  摘要：

  该发明提供了一类新型化合物，包括这些化合物的药物组合物以及使用这些化合物治疗或预防与异常或失调的激酶活性相关的疾病或障碍的方法，特别是涉及FAK、Abl、BCR-Abl、PDGF-R、c-Kit、NPM-ALK、Flt-3、JAK2和c-Met激酶异常激活的疾病或障碍。

  公开号：

  WO2005080393A1
• 作为产物：
  描述：

  2-氯-5-(2-乙氧基乙烯基)-嘧啶-4-胺 在 盐酸 、 potassium phosphate 、 copper(l) iodide 、 (1S,2S)-(+)-1,2-环己二胺 作用下， 以 1,4-二氧六环 、 异丙醇 为溶剂， 反应 6.0h， 生成 2-chloro-7-pyridin-2-yl-7H-pyrrolo[2,3-d]pyrimidine
  参考文献：
  名称：

  设计和合成7H-吡咯并[2,3-d]嘧啶作为粘着斑激酶抑制剂。第1部分。

  摘要：

  设计并合成了一系列2-氨基-9-芳基-7H-吡咯并[2,3-d]嘧啶，以靶向粘着斑激酶（FAK）。许多这些吡咯并嘧啶对粘着斑激酶表现出低的微摩尔抑制活性，并且它们的初步SAR是通过系统化学修饰而建立的。2-氨基-9-芳基-7H-吡咯并[2,3-d]嘧啶代表了一类新的激酶抑制剂。

  DOI：

  10.1016/j.bmcl.2006.01.053

文献信息

• [EN] COMPOUNDS AND COMPOSITIONS AS INDUCERS OF KERATINOCYTE DIFFERENTIATION<br/>[FR] COMPOSES ET COMPOSITIONS EN TANT QU'INDUCTEURS DE LA DIFFERENCIATION DE KERATINOCYTES
  申请人：IRM LLC

  公开号：WO2005107760A1

  公开（公告）日：2005-11-17

  The invention provides compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to induce undifferentiated keratinocytes to differentiate into terminally differentiated keratinocytes. The invention further provides compounds for the treatment of diseases or disorders associated with casein kinase II (CK2), TANK-binding kinase 1 (TBK1) and NIMA-related kinase 9 (NEK9).

  这项发明提供了化合物、包含这些化合物的药物组合物以及使用这些化合物诱导未分化角质细胞分化为终末分化角质细胞的方法。该发明还提供了用于治疗与酪蛋白激酶II（CK2）、TANK结合激酶1（TBK1）和NIMA相关激酶9（NEK9）相关的疾病或疾病的化合物。
• Compounds and Compositions as Protein Kinase Inhibitors
  申请人：Choi Ha-Soon

  公开号：US20070225306A1

  公开（公告）日：2007-09-27

  The invention provides a novel class of compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated kinase activity, particularly diseases or disorders that involve abnormal activation of the FAK, Abl, BCR-Abl, PDGF-R, c-Kit, NPM-ALK, Flt-3, JAK2 and c-Met kinases.

  这项发明提供了一类新型化合物，包括这些化合物的药物组合物和使用这些化合物治疗或预防与异常或非调节性激酶活性相关的疾病或障碍的方法，特别是涉及FAK、Abl、BCR-Abl、PDGF-R、c-Kit、NPM-ALK、Flt-3、JAK2和c-Met激酶异常激活的疾病或障碍。
• Substituted pyrrolo[2,3-2]pyrimidines as protein kinase inhibitors
  申请人：Novartis AG

  公开号：US07968557B2

  公开（公告）日：2011-06-28

  The invention provides a novel class of compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated kinase activity, particularly diseases or disorders that involve abnormal activation of the FAK, Abl, BCR-Abl, PDGF-R, c-Kit, NPM-ALK, Flt-3, JAK2 and c-Met kinases.

  本发明提供了一类新型化合物、包含此类化合物的药物组合物以及使用此类化合物治疗或预防与异常或失调激酶活性相关的疾病或障碍的方法，特别是涉及FAK、Abl、BCR-Abl、PDGF-R、c-Kit、NPM-ALK、Flt-3、JAK2和c-Met激酶异常激活的疾病或障碍。
• Novel Mps1 kinase inhibitors: From purine to pyrrolopyrimidine and quinazoline leads
  作者：Matthew G. Bursavich、David Dastrup、Mark Shenderovich、Kraig M. Yager、Daniel M. Cimbora、Brandi Williams、D. Vijay Kumar

  DOI：10.1016/j.bmcl.2013.10.008

  日期：2013.12

  Mps1, also known as TTK, is a mitotic checkpoint protein kinase that has become a promising new target of cancer research. In an effort to improve the lead-likeness of our recent Mps1 purine lead compounds, a scaffold hopping exercise has been undertaken. Structure-based design, principles of conformational restriction, and subsequent scaffold hopping has led to novel pyrrolopyrimidine and quinazoline Mps1 inhibitors. These new single-digit nanomolar leads provide the basis for developing potent, novel Mps1 inhibitors with improved drug-like properties. (C) 2013 Elsevier Ltd. All rights reserved.
• The synthesis and SAR of 2-amino-pyrrolo[2,3-d]pyrimidines: A new class of Aurora-A kinase inhibitors
  作者：Kevin J. Moriarty、Holly K. Koblish、Thomas Garrabrant、Jahanvi Maisuria、Ehab Khalil、Farah Ali、Ioanna P. Petrounia、Carl S. Crysler、Anna C. Maroney、Dana L. Johnson、Robert A. Galemmo

  DOI：10.1016/j.bmcl.2006.08.080

  日期：2006.11

  A new class of Aurora-A inhibitors have been identified based on the 2-amino-pyrrolo[2,3-d]pyrimidine scaffold. Here, we describe the synthesis and SAR of this novel series. We report compounds which exhibit nanomolar activity in the Aurora-A biochemical assay and are able to inhibit tumor cell proliferation. This study culminates in compound 30, an inhibitor with potent activity against Aurora A (IC50 = 0-008 mu M), anti-proliferative activity against several tumor cell lines and induces polyploidy in H460 cells. (c) 2006 Elsevier Ltd. All rights reserved.